Preventive treatments for recurrence after curative resection of hepatocellular carcinoma - A literature review of randomized control trials

Table 4 A summary of RCT results of adoptive immunotherapy to prevent recurrence

Authors	Entry criteria	Treatment protocol	Sample size	Observation	DFS	OS	Conclusions
			(Tx/Ctl)	time	Tx vs Ctl	Tx vs Ctl
Une[30]	NA	A ia vs A + LAK and IL2 ia	24 (12/12)	NA	50% vs 8.3%	NA	Beneficial
Kawata[31]	NA	A ia vs A + IL2 + LAK ia	24 (12/12)	NA	NS	NA	Not beneficial
Lygidakis[32]	NA	No Tx vs	40 (20/20)	NA	Recurrence:	NA	Beneficial
		Chemoimmunotherapy			0/18 vs 7/17
Takayama[1]	Completely remove;	LAK IV at the 2nd,	155 (76/79)	> 5 years	3-year	5-year	Beneficial
	histologically negative	3rd, 4th, 12th, 24th week			48% vs 33%	68% vs 62%
	in surgical margin	after operation			5 year 37% vs 22%

ia: Intra-arterially; iv: Intravenously; NA: Not available; NS: Not significant; DFS: Disease free survival; OS: Overall survival; Tx: Treatment; Ctl: Control; LAK: Lymphokine activated killer cells; NA: Not available.